TY - JOUR
T1 - Triptolide and Its Derivatives as Cancer Therapies
AU - Noel, Pawan
AU - Von Hoff, Daniel D.
AU - Saluja, Ashok K.
AU - Velagapudi, Mohana
AU - Borazanci, Erkut
AU - Han, Haiyong
N1 - Funding Information:
This work was supported in part by a Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (Grant No. SU2C-AACR-DT-20-16), the Seena Magowitz Foundation for Pancreatic Cancer Research, and National Foundation for Cancer Research. Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.
Funding Information:
This work was supported in part by a Stand Up To Cancer-Cancer Research UK- Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (Grant No. SU2C-AACR-DT-20-16 ), the Seena Magowitz Foundation for Pancreatic Cancer Research, and National Foundation for Cancer Research . Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research , the scientific partner of SU2C.
PY - 2019/5
Y1 - 2019/5
N2 - Triptolide, a compound isolated from a Chinese medicinal herb, possesses potent antitumor, immunosuppressive, and anti-inflammatory properties, but is clinically limited due to its poor solubility, bioavailability, and toxicity. Recently, Minnelide, a water-soluble prodrug of triptolide, was shown to have potent antitumor activity in various preclinical cancer models. Minnelide is currently in Phase II clinical trials for treatment of advanced pancreatic cancer, which has fueled increased interest in this promising agent. Here, we review the recent advances in the biological activity of triptolide and its analogs, their mechanisms of actions, and their clinical developments. A special emphasis is given to proteins and pathways within the tumor and stromal compartments that are targeted by triptolide and its analogs as well as the ongoing clinical trials.
AB - Triptolide, a compound isolated from a Chinese medicinal herb, possesses potent antitumor, immunosuppressive, and anti-inflammatory properties, but is clinically limited due to its poor solubility, bioavailability, and toxicity. Recently, Minnelide, a water-soluble prodrug of triptolide, was shown to have potent antitumor activity in various preclinical cancer models. Minnelide is currently in Phase II clinical trials for treatment of advanced pancreatic cancer, which has fueled increased interest in this promising agent. Here, we review the recent advances in the biological activity of triptolide and its analogs, their mechanisms of actions, and their clinical developments. A special emphasis is given to proteins and pathways within the tumor and stromal compartments that are targeted by triptolide and its analogs as well as the ongoing clinical trials.
KW - Minnelide
KW - stroma
KW - transcription regulation
KW - triptolide
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85063939425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063939425&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2019.03.002
DO - 10.1016/j.tips.2019.03.002
M3 - Review article
C2 - 30975442
AN - SCOPUS:85063939425
VL - 40
SP - 327
EP - 341
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
SN - 0165-6147
IS - 5
ER -
